CG Oncology, Inc.

CGON

US1569441009

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 00:00:00 17/01/2026 +03			5-day change	1st Jan Change
54.73 ^USD	+3.13%		+30.53%	+31.82%

01-09	Top Midday Gainers	MT
01-09	CG Oncology to Share Data From Phase 3 Bladder Cancer Trial a Year Ahead of Schedule; Shares Up	MT

Cg Oncology provides updated timeline for Pivot-006 phase 3 topline data in intermediate-risk NMIBC

Published on 01/09/2026 at 05:20 pm +03

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about CG Oncology, Inc.

01-09	Top Midday Gainers	MT
01-09	CG Oncology to Share Data From Phase 3 Bladder Cancer Trial a Year Ahead of Schedule; Shares Up	MT
01-09	CG Oncology, Inc. Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC	CI
01-09	Cg Oncology provides updated timeline for Pivot-006 phase 3 topline data in intermediate-risk NMIBC	RE
01-09	CG Oncology to Share Data for Investigational Bladder Cancer Therapy Nearly a Year Early	MT
01-06	BofA Adjusts Price Target on CG Oncology to $62 From $60, Maintains Buy Rating	MT
12-11	Wedbush Initiates CG Oncology at Outperform With $70 Price Target	MT
12-05	CG Oncology, Inc. Announces New Cretostimogene Grenadenorepvec Data Highlight Its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer	CI
12-05	CG Oncology Inc - announced topline data from Bond-003 cohort P and first results from Core-008 cohort A	RE
11-26	CG Oncology, Inc. Announces Board and Committee Changes	CI
11-26	CG Oncology, Inc. to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology 26th Annual Meeting	CI
11-17	Centessa Pharmaceuticals, CG Oncology Drive Q3 Biotech Momentum, Morgan Stanley Says	MT
11-17	RBC Raises Price Target on CG Oncology to $61 From $53, Keeps Outperform, Speculative Risk	MT
11-17	Morgan Stanley Raises Price Target to CG Oncology to $82 From $79, Keeps Overweight Rating	MT
11-15	Robert Lapetina resigned as CG Oncology's interim financial officer on Nov 10 - SEC filing	RE
11-15	CG Oncology, Inc. Announces Principal Financial and Accounting Officer Changes	CI
11-15	CG Oncology, Inc. Announces Interim Principal Financial Officer Changes	CI
11-14	CG Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-14	CG Oncology Q3 Net Loss Widens; Revenue Rises	MT
11-14	Earnings Flash (CGON) CG Oncology, Inc. Reports Q3 Revenue $1.7M	MT
11-14	Earnings Flash (CGON) CG Oncology Posts Q3 Net Loss $0.57 a Share, vs. FactSet Est of $0.57 Loss	MT
08/10/25	Guggenheim Initiates Coverage on CG Oncology With Buy Rating, $90 Price Target	MT
30/09/25	CG Oncology Insider Sold Shares Worth $499,868, According to a Recent SEC Filing	MT
22/09/25	CG Oncology Insider Sold Shares Worth $884,909, According to a Recent SEC Filing	MT
15/09/25	CG Oncology Insider Bought Shares Worth $49,999,983, According to a Recent SEC Filing	MT

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Companyâs product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Employees

113

Sector

Biotechnology & Medical Research

Calendar

03-27 - Q4 2025 Earnings Release (Projected)

More about the company